Angelini Ventures and EIB Inject $58M into Rouge Therapeutics to Tackle Hereditary Hemorrhagic Telangiectasia

Angelini Ventures and the European Investment Bank (EIB) have co-led a $58 million Series A financing round in Rouge Therapeutics, a biotech company developing a first-in-class treatment for hereditary hemorrhagic telangiectasia (HHT). The deal, announced on [date], marks the fourth investment completed under Angelini Ventures' €150 million co-investment partnership with the EIB in less than 12 months. Regina Hodits, Managing Director of Angelini Ventures, highlighted the milestone, noting the rapid deployment of the partnership's capital.

The funding will support Rouge Therapeutics in advancing its novel therapy for HHT, a rare genetic disorder that causes abnormal blood vessel formation and can lead to severe bleeding. The €150 million partnership between Angelini Ventures and the EIB, launched in [year], aims to back innovative life sciences companies across Europe. This latest investment underscores the growing interest in rare disease treatments, where unmet medical needs remain high. "We are thrilled to co-lead this round and support Rouge Therapeutics' promising approach," said Hodits.

The investment is expected to accelerate clinical development of Rouge's HHT treatment, potentially bringing a much-needed option to patients. It also signals increasing momentum in European biotech funding, particularly for rare diseases, as public and private investors collaborate to de-risk early-stage innovation. The next steps for Rouge Therapeutics include initiating clinical trials and expanding its team, with the goal of achieving key milestones in the coming years.